Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

BACKGROUND: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PCSK9) under investigation for treatment of hypercholesterolemia and reduction of cardiovascular events. METHODS/DESIGN: The COMBO studies, part of the Phase 3 ODYSSEY clinical trial program...

Descripción completa

Detalles Bibliográficos
Autores principales: Colhoun, Helen M, Robinson, Jennifer G, Farnier, Michel, Cariou, Bertrand, Blom, Dirk, Kereiakes, Dean J, Lorenzato, Christelle, Pordy, Robert, Chaudhari, Umesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190302/
https://www.ncbi.nlm.nih.gov/pubmed/25240705
http://dx.doi.org/10.1186/1471-2261-14-121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190302/
https://www.ncbi.nlm.nih.gov/pubmed/25240705
http://dx.doi.org/10.1186/1471-2261-14-121

Ejemplares similares